WHA, is not yet receiving SMRA/CFDA approval for its infant formula, but
Further to our announcement of 6 April 2018, WHA has passed technical evaluation
for State Administration for Market Regulation (SAMR, formerly known as CFDA)
accreditation for China. WHA is now waiting for formal approval and attainment of
SAMR, on receipt of which revenue is projected to reach in excess of $140 million over
a 42-month period in the China market.
Cash at bank at the end of the quarter was around $50 million with nil debt.
$3 is coming, page-539
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
